MENLO PARK, Calif., Jan. 11 ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Dip and Read Residual Protein A Detection Kit for use on the company's Octet platform. The new assay enables drug developers to accurately identify and measure levels of Protein A with unprecedented speed and minimal hands-on time. The company also announced the introduction of its Sidekick Offline Biosensor Immobilization Station, which enables offline loading of reagents on biosensors, in tandem with any Octet instrument, for enhanced efficiency and assay performance.
Advertisement
The Dip and Read Residual Protein A Detection Kit consists of biosensors and all the reagents required to quantitate Protein A or biosimilars such as MabSelect SuRe(TM), in the presence of human IgG.
Advertisement
"Protein A detection is a critical quality control step during drug development and manufacturing, but traditional methods are labor-intensive, complicated and time-consuming," said Christopher Silva, ForteBio's vice president of marketing. "Our new Dip and Read Residual Protein A Detection Kit offers the same sensitivity levels as existing methods, but requires significantly less hands-on time and can be completed in half the time."
The new Sidekick Offline Biosensor Immobilization Station works alongside any Octet instrument and enables offline, simultaneous and uniform sample loading on all 96 biosensors on a biosensor tray. This increases efficiency by freeing up the Octet system for other uses. Additionally, the instrument shakes the samples, while keeping the biosensors immobile, which decreases the required incubation time by one half, thereby doubling the biosensor preparation productivity. Further, for sandwich assays, this process significantly increases the assay's sensitivity.
"Our Sidekick instrument enables more samples to be run in significantly less time and with greater assay performance. It is ideal for rapid custom biosensor batch preparation and multistep Octet sandwich assays, which are used to detect impurities - such as residual Protein A in therapeutic antibody products," said Mr. Silva.
ForteBio's Octet platform is based on the company's proprietary BioLayer Interferometry (BLI) technology, which uses optical biosensors to measure multiple interactions in parallel, without the use of detection agents. The Octet platform consists of 8- and 16-channel instruments that accommodate 96- and 384-well assay formats. All Octet biosensors are designed to simplify quantitation and kinetic characterization by eliminating throughput limitations of traditional SPR-based systems. The Octet biosensors are disposable, configured in a standard microplate format and are coated with a proprietary biocompatible matrix that is uniform, non-denaturing and has minimal non-specific binding.
About ForteBio, Inc.
ForteBio is a life science company that provides analytical systems to accelerate biotherapeutic drug discovery and development. These systems enable real-time, label-free analysis of biomolecular interactions, providing information on affinity, kinetics and concentration. ForteBio's analytical capabilities enable significantly easier, faster and better characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California, with wholly owned subsidiaries in London and Shanghai. For more information, visit www.fortebio.com.
CONTACT: Gemma Milan 650-289-6800 [email protected]
SOURCE ForteBio, Inc.
